140 related articles for article (PubMed ID: 11447742)
1. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas.
Ross JS; Sheehan CE; Williams SS; Malfetano JH; Szyfelbein WM; Kallakury BV
Am J Clin Pathol; 2001 Jul; 116(1):122-8. PubMed ID: 11447742
[TBL] [Abstract][Full Text] [Related]
2. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.
Kayastha S; Freedman AN; Piver MS; Mukkamalla J; Romero-Guittierez M; Werness BA
Clin Cancer Res; 1999 May; 5(5):1073-6. PubMed ID: 10353740
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
5. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression.
Saegusa M; Machida D; Hashimura M; Okayasu I
J Pathol; 1999 Nov; 189(3):326-37. PubMed ID: 10547593
[TBL] [Abstract][Full Text] [Related]
6. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
7. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
8. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
[TBL] [Abstract][Full Text] [Related]
9. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
10. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
11. Expression of standard CD44 in human colorectal carcinoma: association with prognosis.
Huh JW; Kim HR; Kim YJ; Lee JH; Park YS; Cho SH; Joo JK
Pathol Int; 2009 Apr; 59(4):241-6. PubMed ID: 19351367
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases.
Schröder W; Rudlowski C; Biesterfeld S; Knobloch C; Hauptmann S; Rath W
Anticancer Res; 1999; 19(5B):3901-6. PubMed ID: 10628329
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
14. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
15. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
16. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
[TBL] [Abstract][Full Text] [Related]
17. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
18. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R
Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of CD44 expression in colorectal carcinomas.
Sökmen S; Lebe B; Sarioglu S; Füzün M; Terzi C; Küpelioglu A; Ellidokuz H
Anticancer Res; 2001; 21(6A):4121-6. PubMed ID: 11911305
[TBL] [Abstract][Full Text] [Related]
20. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma.
Shigemasa K; Gu L; O'Brien TJ; Ohama K
Clin Cancer Res; 2003 May; 9(5):1756-63. PubMed ID: 12738731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
